Prognostic value of right ventricular-pulmonary artery coupling in patients with muscular dystrophies
Related Experiment Video
Updated: Feb 14, 2026

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
Published on: June 27, 2025
Abdallah Fayssoil1,2,3,4, Nicolas Mansencal5, Cendrine Chaffaut6
1Department of Cardiology, Centre de référence des cardiomyopathies et des troubles du rythme cardiaque héréditaires ou rares, Ambroise Paré Hospital, Assistance Publique- Hôpitaux de Paris (AP-HP), Université de Versailles-Saint Quentin (UVSQ), Boulogne-Billancourt, France. abdallah.fayssoil@aphp.fr.
Abstract:
Muscular dystrophies can affect the heart and the respiratory system. Right ventricular‒pulmonary artery (RV‒PA) coupling may reflect right ventricular adaptation to respiratory status. Since RV function is very sensitive to afterload, evaluating RV function coupled with pulmonary circulation is more relevant for assessing clinical issues in patients. The aim of this study was to assess the prognostic value of the tricuspid annular plane systolic excursion/systolic pulmonary artery pressure (TAPSE/sPAP), an index of RV–PA coupling, in patients with Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD) and sarcoglycanopathies. The study included retrospectively, from 2015 to 2023, patients with DMD, BMD and sarcoglycanopathies, who were followed in Pitié-Salpêtrière Hospital and Raymond-Poincaré Hospital (France) and who benefited from echocardiography that included a measurement of TAPSE/sPAP. The primary goal was to assess the prognostic value of the TAPSE/sPAP in terms of predicting cardiac events. The study included 113 patients (median age 28 years): DMD (n = 60, 53%), BMD (n = 33, 29%) and sarcoglycanopathies (n = 20, 18%). Home mechanical ventilation was present in 51 patients (46%), and 69% of the patients were wheelchair bound. Left ventricular systolic dysfunction (LVEF < 50%) was present in 37% of the patients. The median sPAP was 22 mmHg [19–27], whereas the median TAPSE was 16 mm [13–18]. Using a Cox model, we found that the TAPSE/sPAP*10 was significantly associated with cardiac events; the higher the TAPSE/sPAP, the better was the outcome (HR 0.33, 95% CI [0.16–0.69], p 0.003). According to the Youden criterion, the cutoff TAPSE/sPAP*10 was 5.3 mm/mmHg. RV–PA coupling, defined by the TAPSE/sPAP, may be a prognostic biomarker in patients with muscular dystrophies.
More Related Videos
05:54A Simple and Low-cost Assay for Measuring Ambulation in Mouse Models of Muscular Dystrophy
Published on: December 29, 2017
07:02A Large Animal Model for Pulmonary Hypertension and Right Ventricular Failure: Left Pulmonary Artery Ligation and Progressive Main Pulmonary Artery Banding in Sheep
Published on: July 15, 2021
Related Concept Videos
Satellite Stem Cells and Muscular Dystrophy
The Muscular System
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...